HMGNs: The enhancer charmers.
Victoria, Canada. In Bioessays, Jan 2016
For over 35 years, the high-mobility group nucleosome-binding chromosomal proteins HMGN1 and HMGN2 have been shown to play a role in the establishment of these chromatin-accessible domains at transcriptional regulatory elements, namely promoters and enhancers.
HMGN2, a new anti-tumor effector molecule of CD8⁺ T cells.
Chengdu, China. In Mol Cancer, 2013
Our previous research has shown that high mobility group nucleosomal-binding domain 2 (HMGN2) could be released by IL-2 and PHA stimulated peripheral blood mononuclear cells (PBMCs) and also induced tumor cells apoptosis at low doses.
A multi-resource data integration approach: identification of candidate genes regulating cell proliferation during neocortical development.
Tallahassee, United States. In Front Neurosci, 2013
We used a mouse in situ hybridization dataset (The Allen Institute for Brain Science) to identify 13 genes (Cdon, Celsr1, Dbi, E2f5, Eomes, Hmgn2, Neurog2, Notch1, Pcnt, Sox3, Ssrp1, Tead2, Tgif2) with high correlation of expression in the proliferating cells of the VZ of the neocortex at early stages of development (E15.5).
HMGNs, DNA repair and cancer.
Bethesda, United States. In Biochim Biophys Acta, 2010
In addition, emerging roles for HMGN5 in cancer progression and for HMGN2 as a potential tool in cancer therapy will be discussed.